Publication Name	World Journal of Clinical Oncology
Manuscript ID	9658
Country	United Kingdom

Received	2014-02-28 14:26
Peer-Review Started	2014-03-06 11:29
To Make the First Decision	2014-03-26 15:15
Return for Revision	2014-03-31 15:50
Revised	2014-04-20 22:15
Second Decision	2014-06-11 13:28
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-06-11 13:44
Articles in Press	2014-06-11 13:44
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-07-21 16:09
Publish the Manuscript Online	2014-08-01 15:17

ISSN	2218-4333 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Pleomorphic lobular carcinoma in situ of the breast: Can the evidence guide practice?
Manuscript Source	Invited Manuscript
All Author List	Andrew Pieri, James Harvey and Nigel Bundred
Funding Agency and Grant Number
Corresponding Author	Nigel Bundred, MD, FRCS, Professor of Surgical Oncology, Nightingale Centre, University Hospital of South Manchester, Wythenshawe Hospital, Southmoor Road, Manchester, M23 9LT, United Kingdom. nigel.j.bundred@manchester.ac.uk
Key Words	Pleomorphic lobular carcinoma in situ; Breast cancer; Breast carcinoma; Carcinoma in situ; Guideline; Excision margin; Recurrence rate
Core Tip	Pleomorphic lobular carcinoma in situ (PLCIS) is a breast lesion, the clinical significance of which is a subject of controversy. To date, this systematic review is the largest pooled series of clinical data regarding PLCIS. We aimed to establish whether current guidelines for management are consistent with the evidence. The results demonstrate a lack of high quality data and guidelines for management are variable. Analysis revealed a high incidence of concurrent invasive disease with PLCIS (49%) and following excision, a recurrence rate of 9.4%. We conclude that it would seem prudent to manage PLCIS as with ductal carcinoma in situ, although there is a dire need for long-term outcome studies.
Publish Date	2014-08-01 15:17
Citation	Pieri A, Harvey J, Bundred N. Pleomorphic lobular carcinoma in situ of the breast: Can the evidence guide practice? World J Clin Oncol 2014; 5(3): 546-553
URL	http://www.wjgnet.com/2218-4333/full/v5/i3/546.htm
DOI	http://dx.doi.org/10.5306/wjco.v5.i3.546

Full Article (PDF)	WJCO-5-546.pdf
Full Article (Word)	WJCO-5-546.doc
Manuscript File	9658-Review.docx
Answering Reviewers	9658-Answering reviewers.pdf
Copyright License Agreement	9658-Copyright assignment.pdf
Peer-review Report	9658-Peer review(s).pdf
Scientific Misconduct Check	9658-CrossCheck.jpg
Scientific Editor Work List	9658-Scientific editor work list.pdf